Focal Segmental Glomerulosclerosis Clinical Trials

A listing of Focal Segmental Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis

This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198

  • 0 views
  • 28 Oct, 2022
  • 26 locations
Obinutuzumab in Primary FSGS

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

  • 2 views
  • 07 Oct, 2022
  • 1 location
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (ACTION3)

placebo over a treatment period of 104 weeks in adult patients with biopsy-proven FSGS who are being treated with an ARB.

sglt2
corticosteroids
kidney biopsy
total protein
treatment regimen
  • 2 views
  • 04 Oct, 2022
  • 39 locations
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases (EPPIK)

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period.

mammogram
glomerular filtration rate
corticosteroids
kidney biopsy
total protein
  • 1 views
  • 11 Oct, 2022
  • 26 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

immunosuppressants
kidney function tests
atrasentan
corticosteroids
renal function
  • 31 views
  • 04 Oct, 2022
  • 36 locations
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who

focal segmental glomerulosclerosis
corticosteroids
kidney biopsy
minimal change disease
treatment regimen
  • 0 views
  • 04 Oct, 2022
  • 8 locations
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change

focal segmental glomerulosclerosis
segmental glomerulosclerosis
glomerulosclerosis
minimal change disease
proteinuria
  • 0 views
  • 07 Oct, 2022
  • 17 locations
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).

focal segmental glomerulosclerosis
angiotensin converting enzyme
kidney biopsy
total protein
minimal change disease
  • 12 views
  • 04 Oct, 2022
  • 3 locations
The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant

This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.

acthar
kidney transplant
  • 35 views
  • 13 Oct, 2022
  • 1 location
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)

- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD).

  • 0 views
  • 14 Oct, 2022
  • 1 location